Pre-made Natalizumab benchmark antibody ( Whole mAb, anti-ITGA4 therapeutic antibody, Anti-CD49D/IA4 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Natalizumab biosimilar, Whole mAb, Anti-ITGA4 Antibody: Anti-CD49D/IA4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Natalizumab, sold under the brand name Tysabri among others, is a medication used to treat multiple sclerosis and Crohn's disease. It is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin. It is given by intravenous infusion every 28 days. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood–brain barrier. Natalizumab has proven effective in treating the symptoms of both diseases, preventing relapse, vision loss, cognitive decline and significantly improving quality of life in people with multiple sclerosis, as well as increasing rates of remission and preventing relapse in multiple sclerosis.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-367-1mg	1mg	3090
GMP-Bios-ab-367-10mg	10mg	Inquiry
GMP-Bios-ab-367-100mg	100mg	Inquiry
GMP-Bios-ab-367-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Natalizumab biosimilar, Whole mAb, Anti-ITGA4 Antibody: Anti-CD49D/IA4 therapeutic antibody
INN Name	Natalizumab
Target	ITGA4
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	4irz:HL
95-98% SI Structure	None
Year Proposed	1998
Year Recommended	1999
Companies	Biogen;Biogen Idec;Elan Corporation;Perrigo
Conditions Approved	Crohn's disease;Multiple sclerosis
Conditions Active	Epilepsy;Graft-versus-host disease;Stroke
Conditions Discontinued	Multiple myeloma;Rheumatoid arthritis
Development Tech	na